Section 1: Biologic Considerations and Myeloma - Staging and Myeloma L.T. Heffner MD- Epidemiology of Multiple Myeloma A.A Langston MD and Dixil Francis- Basic Biology of Plasma Cell Dyscrasias Kenneth Anderson MD, DFCI and Marc S. Raab- Biology Based Classification and Staging of Multiple Myeloma Peter Leif Bergsagel MD and Wee Joo Chng, MD- The importance of FISH and Cytogenetics R. Fonseca MD, Esteban Braggio and Michael Sebag- Section 2: Historical and Cytotoxic Agent based Therapies for Myeloma- Role of Autologous Stem Cell Transplantation In Multiple Myeloma J.L. Harrouseau, MD- Maintenance Therapy In Multiple Myeloma Jonathan L. Kaufman MD, Ronald Mihelic PharmD, and Sagar Lonial, MD- Therapy for Patients not Eligible for Autologous Transplant Antonio Palumbo, MD and Sara Bringhen, MD- Current Role of Anthracyclines in the Treatment of Multiple Myelma, A. Chanan-Khan, MD and Sikander Ailawadhi- Section 3: Immune Based Therapies- Allogeneic Transplantation for Multiple Myeloma Edmund K. Waller MD, PhD Fengrong Wang, MD - Immunobiology and Immunotherapy of Multiple Myeloma Madhav Dhodapkar MD- Antibody and other Immune based therapies for Myeloma N Munshi MD, DFCI- Section 4: Existing novel agents - Thalidomide In Relapsed Multiple Myeloma Patients Ashraf Badros MD- Thalidomide: Induction Therapy S. Vincent Rajkumar MD and Francis K. Baudi, MD- The Role of Bortezomib In the Treatment of Relapsed and Refractory Multiple Myeloma Paul G. Richardson MD, DFCI, Constantine S. Mitsiades, Robert Schlossman, Irene Ghobrial, Nikhil C. Munshi and Kenneth C. Anderson- Bortezomib As Induction Therapy In Multiple Myeloma Patients J San Miguel MD,PhD and M.V. Mateos, MD, PhD- Lenalidomide In Relapsed and Refractory Multiple Myeloma Donna M. Weber MD, Sheeba K. Thomas MD, Tiffany A. Richards, MS, ANP, AOCNP- Lenalidomide (Revlimid®) For Initial Therapy of Newly Diagnosed Multiple Myeloma Shaji Kumar MD- Section 5: Current and Future Targets- The Role of Heat Shock Protein 90 As A Therapeutic Target for Multiple Myeloma Constantine Mitsiades MD, DFCI, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. Anderson- The P13 Kinase/AKT Pathway As A therapeutic Target for Multiple Myeloma Donald Harvey, PharmD, Jeanine Silberman, MD and Sagar Lonial MD- The Mammalian Target of Rapamycin (mTOR) and Multiple Myeloma Patrick Frost, PhD Alan Lichtenstein, MD- CDK Inhibitors In Multiple Myeloma Yun Dai and Steven Grant MD, MCV- Fibroblast growth factor receptor 3 (FGFR3) and Multiple Myeloma (MM) Victor Hugo Jimenez-Zepeda, MD and Keith Stewart MD- Histone Deacetylase Inhibitors In Multiple Myeloma Teru Hideshima MD, PhD, DFCI- Death Receptors In Multiple Myeloma and Therapeutic Opportunities, F. Mollinedo, PhD- Proteasome Inhibitors as Therapy in Multiple Myeloma Dharminder Chauhan PhD, Ajita Singh, PhD and Kenneth Anderson, MD- Section 6: Supportive Care- Pathophysiology of Bone Disease in Multiple Myeloma Tomer M. Mark, MD and Roger N. Pearse MD, PhD - Anemia and Erythropoeitic Growth Factors in Multiple Myeloma N Raje MD, DFCI- Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Non-Pathologic Fractures Sandra Narayanan, MD and Frank Tong MD- The Role of Anatomic and Functional Imaging In Myeloma Brian Durie MD, - Management of Multiple Myeloma Patients With Renal Dysfunction Sikander Ailawadhi and Asher Chanan-Khan- Section 7: Other Plasma cell Disorders- Waldenström s Macroglobulinemia Lijo Simpson MD and Morie Gertz MD- AL (Immunoglobulin Light-Chain) Amyloidosis Vaishali Sanchorawala, - Poems Syndrome and Other Atypical Plasma Cell Disorders Angela Dispenzeri MD- Monoclonal Gammopathy of Undetermined Significance Robert A. Kyle MD and S. Vincent Rajkumar, MD
EAN/ISBN : 9781597455640
Publisher(s): Springer, Berlin, Humana Press
Format: ePub/PDF

Author(s): Karp, Judith E. - Lonial, Sagar